Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 240

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 18
Chunk 240
---
--------------------------------------------------------
Expected dividend yield                        $0.00    
Weighted average expected volatility              65   %
Weighted average risk-free rate                 4.47   %
Weighted average expected life (years)          1.19    
Share price                                    $6.99    
Weighted average exercise price               $87.04    
Weighted average fair value                    $0.02    

(5)                                                The                                              
       identifiable intangible assets consist of patents expiring between 2027 and 2041 which will  
        be amortized on their respective remaining patent life. To estimate the fair value of the   
      intangible assets, management uses the royalty relief method to value patents using discounted
         cash flow models. Management developed assumptions related to revenue, royalty rates and   
                                             discount rates.                                        
----------------------------------------------------------------------------------------------------

For the period subsequent to the Transaction, Aeterna contributed revenue of $1,095 and net loss of $5,607 to the Company’s results. If the acquisition had occurred on January 1, 2024, management estimates that revenue would have been $9,593 and consolidated net loss for the year would have been $24,972. In determining these amounts, management has assumed that the fair value adjustments that arose on the date of acquisition would have been the same if the acquisition had occurred on January 1, 2024.
 
The Company incurred acquisition-related costs of $4,081 on legal fees and due diligence costs. These costs have been included in Selling, general and administrative expenses as incurred.
 
 
F-23
----
COSCIENS Biopharma Inc.
 Notes to Consolidated Financial Statements As of December 31, 2024 and 2023 and for the years ended December 31, 2024, 2023 and 2022 
(in thousands of US dollars, except share and per share data and where otherwise noted) 

6.   Revenue
------------
 
Disaggregation of revenue
 
The Company derives revenue from the transfer of goods and services at a point in time in the following categories and regions:
  Summary of revenue from transfer of goods and services
 
                   Active Ingredients               Biopharmaceutical                Total      
------------------------------------------------------------------------------------------------
                 Year ended December 31, 2024                                                   
                 Active Ingredients                Biopharmaceutical               Total        
                 $                                 $                               $            
United States                6,691                            -                         6,691   
Germany                      1,360                            -                         1,360   
Colombia         300                                          -